BLOG

Precision Medicine

Elicio Therapeutics Begins Phase II Cancer Vaccine Trial in KRAS-Mutant Pancreatic Cancer

Elicio Therapeutics on Thursday began treating patients with KRAS-mutant pancreatic ductal carcinoma in the Phase II portion of the AMPLIFY-7P trial in which it is testing the cancer vaccine ELI-002 7P as an adjuvant treatment.